MedTrace Logo

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

NCT01957709 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-07-10

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of tumor cells.

Conditions

  • Myxoid Liposarcoma
  • Round Cell Liposarcoma
  • Synovial Sarcoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Recombinant Interferon Gamma

Given subcutaneously weekly for four weeks prior to surgery.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Horizon Pharma USA, Inc.

    collaborator INDUSTRY

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Seth Pollack · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-25
Primary Completion
2018-06-01
Completion
2018-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01957709 on ClinicalTrials.gov